Triplet regimens combining epigenetic unlocking (hypomethylating agents, HMAs), lineage switching (menin inhibition), and apoptosis priming (venetoclax) have shown enhanced CR rates in early trials, with a 2025 study reporting 55% CR in NPM1-mutated AML with menin inhibitor + venetoclax + azacitidine (Zeidner et al., 2025a). Here, MEN1 is linked to acute myeloid leukemia.